Medicare GLP-1 Bridge: New $50 Copay for Weight Loss Medications Starting July 2026
For years, Medicare has largely barred coverage for weight loss treatments, leaving many seniors to face daunting out-of-pocket costs for highly effective GLP-1 medications. That is changing. Starting July 1, 2026, eligible Medicare beneficiaries can access select weight loss drugs for a predictable $50 monthly copayment through a new initiative called the Medicare GLP-1 Bridge.
While this program represents a significant shift in accessibility, it is a time-limited pilot with specific eligibility requirements and financial caveats that patients must understand before applying.
- Program Duration: July 1, 2026, through December 31, 2027.
- Cost: A flat $50 monthly copay regardless of dosage.
- Requirement: Must be enrolled in a Medicare Part D prescription drug plan.
- Eligibility: Based on Body Mass Index (BMI) and accompanying health conditions.
What is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge is a short-term pilot program announced by the Centers for Medicare & Medicaid Services (CMS). It is designed to “bridge” the gap in coverage while the government determines the viability of a longer-term program potentially starting in 2028.
The program specifically covers GLP-1 medications approved for weight loss. The covered medications include:
- Wegovy: Both the injectable and pill formulations.
- Zepbound: The KwikPen formulation.
- Foundayo: The pill formulation.
Who Qualifies for the $50 Copay?
To participate, you must first be enrolled in a Medicare Part D plan. Beyond that, eligibility is determined by clinical guidelines regarding body weight and health status:
- Automatic Qualification: Individuals with a Body Mass Index (BMI) of 35 or higher.
- Conditional Qualification: Individuals with a BMI of 27 or higher who also have a qualifying condition, such as prediabetes or heart disease.
For those already taking these medications for weight loss before the program begins, you may still qualify. Your healthcare provider must attest that you met the clinical BMI criteria at the time you started the therapy.
How the Program Works
The GLP-1 Bridge does not operate like a standard Medicare benefit. It bypasses your regular Part D plan’s formulary and pricing structure. Instead, the process follows these steps:
- Prior Authorization: Your doctor must submit a prior authorization request.
- Centralized Processing: Prescriptions are sent to a central system managed by Humana, a CMS contractor.
- Pharmacy Pickup: Once approved, you pay the flat $50 copayment directly at the pharmacy.
Notably, doctors do not need to be enrolled as Medicare providers to write prescriptions or submit authorization requests under this specific program.
Important Financial Caveats
While $50 is significantly lower than the cash prices—which can range from $149 to $699 per month—the program has several limitations that may impact your overall healthcare spending:
No Contribution to Annual Caps
The $50 copayment is separate from your standard Part D benefits. It does not count toward your Part D deductible, nor does it apply toward the $2,100 annual out-of-pocket cap on prescription drug costs.
Low-Income Subsidy Restrictions
Beneficiaries who use the Medicare Extra Help program (the low-income subsidy) cannot apply that assistance to the medications covered by the GLP-1 Bridge. For patients accustomed to $5 or $10 copays, the $50 cost may still represent a financial barrier.
Weight Loss vs. Other Conditions
This program is exclusively for weight loss. If you take a GLP-1 medication for Type 2 diabetes, sleep apnea, or cardiovascular disease risk reduction, you will continue to receive that medication through your regular Part D plan at your plan’s specific pricing.
The Future of Medicare Weight Loss Coverage
The Bridge program was extended to 18 months (ending December 2027) after a proposed longer-term plan failed to attract enough participating insurers by the April deadline. This extension allows insurance companies to gather more data on usage rates before negotiating further with the administration.
However, the transition remains uncertain. Juliette Cubanski, deputy director of the Program on Medicare Policy at KFF, notes that the program is likely to cost Medicare billions of dollars annually because it heavily subsidizes the drugs. Because the program ends in late 2027, patients face the risk of weight regain if a permanent coverage solution is not established by 2028.
Frequently Asked Questions
Q: Can I use the Bridge program if I don’t have Part D?
A: No. Enrollment in a Medicare Part D prescription drug plan is a mandatory requirement for participation.
Q: Does the $50 copay increase if my dose increases?
A: No. One of the primary benefits of the Bridge program is the predictable flat fee, which remains $50 regardless of the dosage level.
Q: What happens if I lose weight and my BMI drops below 35 before July 2026?
A: If you were already on the medication and met the BMI criteria when you started, your prescriber can attest to this in the prior authorization request to maintain your eligibility.
Disclaimer: This information is based on current CMS pilot program announcements. Patients should consult with their primary care provider and review their specific Medicare Part D plan details to determine eligibility and coverage.